Innovent Biologics, Inc.
1801
Rang în acțiuni
#1176
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou,... Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
Preț acțiune
$11.30
Capitalizare de piață
$19.71B
Schimbare (1 zi)
-0.79%
Schimbare (1 an)
1.97%
Țară
CN
Tranzacționează Innovent Biologics, Inc. (1801)
Categorie
Healthcare
EPS pentru Innovent Biologics, Inc. (1801)
EPS la data de June 2026 TTM: $0.10
Conform celor mai recente rapoarte financiare și prețului acțiunilor Innovent Biologics, Inc., EPS-ul actual al companiei (TTM) este $0.10. La sfârșitul anului 2023, compania avea un EPS de $-0.09 o scădere comparativ cu EPS-ului din 2022, care a fost de $-0.21.
Istoricul EPS pentru Innovent Biologics, Inc. din 2016 până în 2026
EPS la sfârșitul fiecărui an
| An | EPS | Schimbă |
|---|---|---|
| 2026 (TTM) | $0.10 | -1,129.00% |
| 2024 | $-0.01 | -91.42% |
| 2023 | $-0.09 | -55.98% |
| 2022 | $-0.21 | -28.43% |
| 2021 | $-0.30 | 161.08% |
| 2020 | $-0.11 | -47.76% |
| 2019 | $-0.22 | -91.35% |
| 2018 | $-2.51 | 3,163.41% |
| 2017 | $-0.08 | 18.52% |
| 2016 | $-0.06 | 0.00% |
EPS pentru companii similare sau concurente
| Companie | EPS | Diferență EPS | Țara |
|---|---|---|---|
| $17.32 | 16,731.88% |
US
|
|
| $-7.98 | -7,855.10% |
US
|
|
| $-5.29 | -5,240.91% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 26,858.21% |
NL
|
